Wedbush Securities Inc Viking Therapeutics, Inc. Transaction History

Wedbush Securities Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	SELL	$8.08 - $17.33 $3,232 - $6,931	-400 Reduced 2.7%	14,400 $240,000
Q4 2021 Jan 13, 2022	SELL	$4.6 - $6.72 $7,819 - $11,424	-1,700 Reduced 10.3%	14,800 $68,000
Q3 2021 Oct 08, 2021	BUY	$5.58 - $7.04 $92,070 - $116,160	16,500 New	16,500 $103,000
Q2 2021 Jul 27, 2021	SELL	$5.19 - $6.73 $85,635 - $111,045	-16,500 Closed	0 $0
Q1 2021 Apr 26, 2021	SELL	$5.74 - $9.67 $14,350 - $24,175	-2,500 Reduced 13.16%	16,500 $104,000
Q4 2020 Feb 16, 2021	SELL	$5.3 - $6.71 $13,250 - $16,775	-2,500 Reduced 11.63%	19,000 $107,000
Q3 2020 Oct 20, 2020	BUY	$5.73 - $8.11 $14,325 - $20,275	2,500 Added 13.16%	21,500 $125,000
Q1 2020 Apr 17, 2020	SELL	$3.45 - $7.95 $714 - $1,645	-207 Reduced 1.08%	19,000 $89,000
Q3 2019 Oct 17, 2019	BUY	$6.55 - $8.6 $49,125 - $64,500	7,500 Added 64.06%	19,207 $132,000
Q2 2019 Aug 01, 2019	BUY	$7.67 - $10.63 $89,792 - $124,445	11,707 New	11,707 $97,000

442

63.3M

6.23M

2.97M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.94B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Wedbush Securities Inc, based on Form 13F filings with the SEC.

Stay updated on Wedbush Securities Inc with notifications on news.